|

Atirmociclib Clinical Trials

3 actively recruiting trials across 3 locations

▼ -1 trial since June 2026

Also known as: CDK4i

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Olema Pharmaceuticals, Inc.1
  • Hoffmann-La Roche1
  • AstraZeneca1

Indications

  • Breast Cancer3
  • Cancer3
  • Metastatic Breast Cancer2
  • ER-positive Breast Cancer1
  • Locally Advanced Breast Cancer1

Gilbert, Arizona1 trial

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Banner MD Anderson Cancer Center

Phase 1

Duarte, California1 trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2

St Louis, Missouri1 trial

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Research Site

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.